2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T656,Melasma is a chronic refractory pigmentation disorder. Kligman triple (KT) formula is the gold standard. A dermocosmetic (DC) serum containing vitamin B3 and 2-mercaptonicotinyl glycine has been developed for melasma. This study assessed the benefits of DC serum compared to KT in melasma. A randomized, single-blind 6-month study was conducted in women with melasma. Subjects were randomized to Group A (morning: serum; evening: cream, for 6 months) or to Group B (1st 3 months: morning: skin hydrating gel; evening: KT, followed by 3 months of DC routine regimen); all subjects applied a sunscreen with an SPF 50+ twice daily. Assessments included MASI, mMASI, IGA, skin hydration, radiance and fine wrinkles, tolerance, and quality of life (QoL) using MELASQOL. Ninety-one women aged 44 ± 6 years of Phototypes III (30%) and IV (36%) were recruited. Both regimens significantly (p < 0.05) improved MASI after 3 months. A clinically relevant difference in favor of KT was observed. Three months after the switch, both Group A (38.1%) and Group B (41.2%) provided a similar significant (p < 0.05) percentage reduction of MASI score, with no between-group difference. The mMASI and IGA showed similar results. QoL and skin hydration significantly (p < 0.05) improved in both groups after 6 months. Skin radiance and fine wrinkles also improved. Global tolerance was better with the DC routine. Both DC routine and KT significantly improved melasma after 3 months of use. DC further improved melasma when replacing KT for 3 further months, with similar results when used alone for 6 months.31:T806,ABSTRACTIntroductionMelasma is a chronic refractory pigmentation disorder. Kligman triple (KT) formula is the gold standard. A dermocosmetic (DC) serum containing vitamin B3 and 2‐mercaptonicotinyl glycine has been developed for melasma. This study assessed the benefits of DC serum compared to KT in melasma.Material and MethodsA randomized, single‐blind 6‐month study was conducted in women with melasma. Subjects were randomized to Group A (morning: serum; evening: cream, for 6 months) or to Group B (1st 3 months: morning: skin hydrating gel; evening: KT, followed by 3 months of DC routine regimen); all subjects applied a sunscreen with an SPF 50+ twice daily. Assessments included MASI, mMASI, IGA, skin hydration, radiance and fine wrinkles, tolerance, and quality of life (QoL) using MELASQOL.ResultsNinety‐one women aged 44 ± 6 years of Phototypes III (30%) and IV (36%) were recruited. Both regimens significantly (p < 0.05) improved MASI after 3 months. A clinically relevant difference in favor of KT was observed. Three months after the switch, both Group A (38.1%) and Group B (41.2%) provided a similar significant (p < 0.05) percentage reduction of MASI score, with no between‐group difference. The mMASI and IGA showed similar results. QoL and skin hydration significantly (p < 0.05) improved in both groups after 6 months. Skin radiance and fine wrinkles also improved. Global tolerance was better with the DC routine.ConclusionsBoth DC routine and KT significantly improved melasma after 3 months of use. DC further improved melasma when replacing KT for 3 further months, with similar results when used alone for 6 months.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"2-mercaptonicotinyl glycine: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on 2-mercaptonicotinyl glycine (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/2-mercaptonicotinyl%20glycine\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"2-mercaptonicotinyl glycine\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/2-mercaptonicotinyl%20glycine\"}]}}"}}]],["$","$L2f",null,{"title":"2-mercaptonicotinyl glycine: Research & Clinical Takeaways","description":"Explore research on 2-mercaptonicotinyl glycine (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1111/jocd.70476","pmid":"41036635","title":"A Novel Dermocosmetic Routine Containing Vitamin B3 and 2‐Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2025-10-02T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70476","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-06","doi":"10.1111/jocd.70476","days":"7","issn":"1473-2130","rank":"8","field":"Clinical Medicine","score":"1","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70476","title":"A Novel Dermocosmetic Routine Containing Vitamin B3 and 2-Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use.","journal":"Journal of cosmetic dermatology","methods":"","results":"Ninety-one women aged 44 ± 6 years of Phototypes III (30%) and IV (36%) were recruited. Both regimens significantly (p < 0.05) improved MASI after 3 months. A clinically relevant difference in favor of KT was observed. Three months after the switch, both Group A (38.1%) and Group B (41.2%) provided a similar significant (p < 0.05) percentage reduction of MASI score, with no between-group difference. The mMASI and IGA showed similar results. QoL and skin hydration significantly (p < 0.05) improved in both groups after 6 months. Skin radiance and fine wrinkles also improved. Global tolerance was better with the DC routine.","abstract":"$30","keywords":["2‐Mercaptonicotinyl glycine","Kligman's formula","Melasma","vitamin B3"],"pubmed_id":"41036635","conclusions":"","publication_date":"2025-10-02T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70476","URL":"https://doi.org/10.1111/jocd.70476","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["A Novel Dermocosmetic Routine Containing Vitamin B3 and 2‐Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use"],"author":[{"given":"Juliane","family":"Rocio","sequence":"first","affiliation":[{"name":"Institute of Dermatology & Aesthetics of Rio de Janeiro Rio de Janeiro Brazil"}]},{"given":"Natalia","family":"Kovylkina","sequence":"additional","affiliation":[{"name":"Vichy Laboratoires International Vichy France"}]},{"given":"Tania","family":"Cestari","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital de Clinicas de Porto Alegre Porto Alegre Brazil"}]},{"given":"Mariana Fajgenbaum","family":"Feiges","sequence":"additional","affiliation":[{"name":"L'Oréal LDB Rio de Janeiro Brazil"}]},{"given":"Erika","family":"Fernandes","sequence":"additional","affiliation":[{"name":"L'Oréal LDB Rio de Janeiro Brazil"}]},{"given":"Claire","family":"Deloche‐Bensmaine","sequence":"additional","affiliation":[{"name":"Vichy Laboratoires International Vichy France"}]},{"given":"Elisa","family":"Caberlotto","sequence":"additional","affiliation":[{"name":"Vichy Laboratoires International Vichy France"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU Nice Université Côte d'Azur Nice France"},{"name":"C3M, INSERM U1065 Université Côte d'Azur Nice France"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"24","archive":["Portico"],"created":{"date-time":"2025-10-02T09:57:20Z","timestamp":1759399040000,"date-parts":[[2025,10,2]]},"indexed":{"date-time":"2025-10-03T00:38:19Z","timestamp":1759451899164,"date-parts":[[2025,10,3]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000,"date-parts":[[2025,10,2]]},"delay-in-days":1,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70476"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-22"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-19"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-02"}],"deposited":{"date-time":"2025-10-02T09:57:25Z","timestamp":1759399045000,"date-parts":[[2025,10,2]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/pcmr.12684","key":"e_1_2_10_2_1","year":"2018","issue":"4","author":"Passeron T.","volume":"31","first-page":"461","unstructured":null,"article-title":"Melasma, a Photoaging Disorder","journal-title":"Pigment Cell & Melanoma Research","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-022-00779-x","key":"e_1_2_10_3_1","year":"2022","issue":"9","author":"Espósito A. C. C.","volume":"12","first-page":"1967","unstructured":null,"article-title":"Update on Melasma‐Part I: Pathogenesis","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"crossref"},{"DOI":"10.36849/JDD.2020.4663","key":"e_1_2_10_4_1","year":"2020","issue":"2","author":"Kagha K.","volume":"19","first-page":"184","unstructured":null,"article-title":"Melasma's Impact on Quality of Life","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2009.03295.x","key":"e_1_2_10_5_1","year":"2009","issue":"11","author":"Ortonne J. P.","volume":"23","first-page":"1254","unstructured":null,"article-title":"A Global Survey of the Role of Ultraviolet Radiation and Hormonal Influences in the Development of Melasma","journal-title":"Journal of the European Academy of Dermatology and Venereology","doi-asserted-by":"crossref"},{"DOI":"10.4103/0019-5154.84722","key":"e_1_2_10_6_1","year":"2011","issue":"4","author":"Achar A.","volume":"56","first-page":"380","unstructured":null,"article-title":"Melasma: A Clinico‐Epidemiological Study of 312 Cases","journal-title":"Indian Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-2494.2007.00415.x","key":"e_1_2_10_7_1","year":"2008","issue":"2","author":"Farage M. A.","volume":"30","first-page":"87","unstructured":null,"article-title":"Intrinsic and Extrinsic Factors in Skin Ageing: A Review","journal-title":"International Journal of Cosmetic Science","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.19677","key":"e_1_2_10_8_1","year":"2024","issue":"5","author":"Pellacani G.","volume":"38","first-page":"12","unstructured":null,"article-title":"Photoprotection: Current Developments and Controversies","journal-title":"Journal of the European Academy of Dermatology and Venereology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2020.03.115","key":"e_1_2_10_9_1","year":"2023","issue":"3","author":"Cohen L.","volume":"89","first-page":"560","unstructured":null,"article-title":"Cutaneous Interaction With Visible Light: What Do We Know?","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/phpp.12736","key":"e_1_2_10_10_1","year":"2022","issue":"3","author":"Pourang A.","volume":"38","first-page":"191","unstructured":null,"article-title":"Effects of Visible Light on Mechanisms of Skin Photoaging","journal-title":"Photodermatology, Photoimmunology & Photomedicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.mad.2021.111525","key":"e_1_2_10_11_1","year":"2021","issue":null,"author":"Ho C. Y.","volume":"198","first-page":null,"unstructured":null,"article-title":"Faces of Cellular Senescence in Skin Aging","journal-title":"Mechanisms of Ageing and Development","doi-asserted-by":"crossref"},{"DOI":"10.3390/cells11162541","key":"e_1_2_10_12_1","year":"2022","issue":"16","author":"Kim J. C.","volume":"11","first-page":null,"unstructured":null,"article-title":"Skin‐Aging Pigmentation: Who Is the Real Enemy?","journal-title":"Cells","doi-asserted-by":"crossref"},{"DOI":"10.1111/exd.13844","key":"e_1_2_10_13_1","year":"2019","issue":"6","author":"Kwon S. H.","volume":"28","first-page":"704","unstructured":null,"article-title":"Melasma: Updates and Perspectives","journal-title":"Experimental Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2021.1914313","key":"e_1_2_10_14_1","year":"2022","issue":"4","author":"Neagu N.","volume":"33","first-page":"1816","unstructured":null,"article-title":"Melasma Treatment: A Systematic Review","journal-title":"Journal of Dermatological Treatment","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-022-00780-4","key":"e_1_2_10_15_1","year":"2022","issue":"9","author":"Cassiano D. P.","volume":"12","first-page":"1989","unstructured":null,"article-title":"Update on Melasma‐Part II: Treatment","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00403-024-02990-6","key":"e_1_2_10_16_1","year":"2024","issue":"7","author":"Shivaram K.","volume":"316","first-page":"378","unstructured":null,"article-title":"An Update on the Safety of Hydroquinone","journal-title":"Archives of Dermatological Research","doi-asserted-by":"crossref"},{"DOI":"10.3390/jcm13237483","key":"e_1_2_10_17_1","year":"2024","issue":"23","author":"Wu B. Q.","volume":"13","first-page":null,"unstructured":null,"article-title":"Clinical Efficacy of Cysteamine Application for Melasma: A Meta‐Analysis","journal-title":"Journal of Clinical Medicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2009.10.051","key":"e_1_2_10_18_1","year":"2011","issue":"1","author":"Pandya A. G.","volume":"64","first-page":"78","unstructured":null,"article-title":"Reliability Assessment and Validation of the Melasma Area and Severity Index (MASI) and a New Modified MASI Scoring Method","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_10_19_1","year":"2017","issue":null,"author":"Flament F.","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2006.07591.x","key":"e_1_2_10_20_1","year":"2006","issue":"1","author":"Cestari T. F.","volume":"156","first-page":"13","unstructured":null,"article-title":"Validation of a Melasma Quality of Life Questionnaire for Brazilian Portuguese Language: The MelasQoL‐BP Study and Improvement of QoL of Melasma Patients After Triple Combination Therapy","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.36849/JDD.7428","key":"e_1_2_10_21_1","year":"2024","issue":"2","author":"Sachdev M.","volume":"23","first-page":"9","unstructured":null,"article-title":"Cysteamine Isobionic‐Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_10_22_1","year":"2024","issue":null,"author":"Schwartz C.","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_23_1","year":"2023","issue":"11","author":"Fabian I. M.","volume":"15","first-page":null,"unstructured":null,"article-title":"Topical Hydroquinone for Hyperpigmentation: A Narrative Review","journal-title":"Cureus","doi-asserted-by":null},{"DOI":"10.1111/ijd.15878","key":"e_1_2_10_24_1","year":"2022","issue":"6","author":"Ishack S.","volume":"61","first-page":"675","unstructured":null,"article-title":"Exogenous Ochronosis Associated With Hydroquinone: A Systematic Review","journal-title":"International Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.16200","key":"e_1_2_10_25_1","year":"2024","issue":"5","author":"Dormael R.","volume":"23","first-page":"1745","unstructured":null,"article-title":"2‐Mercaptonicotinoyl Glycine Prevents UV‐Induced Skin Darkening and Delayed Tanning in Healthy Subjects: A Randomized Controlled Clinical Study","journal-title":"Journal of Cosmetic Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.3390/antiox13040425","key":"e_1_2_10_26_1","year":"2024","issue":"4","author":"Marques C.","volume":"13","first-page":null,"unstructured":null,"article-title":"Mechanistic Insights Into the Multiple Functions of Niacinamide: Therapeutic Implications and Cosmeceutical Applications in Functional Skincare Products","journal-title":"Antioxidants (Basel)","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_10_27_1","year":"2019","issue":"5","author":"Desai S.","volume":"18","first-page":"454","unstructured":null,"article-title":"Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.36849/JDD.7104","key":"e_1_2_10_28_1","year":"2023","issue":"4","author":"Desai S.","volume":"22","first-page":"386","unstructured":null,"article-title":"Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70476"],"article-number":"e70476","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,10]]},"reference-count":27,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,2]]},"references-count":27,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70476","is_oa":true,"title":"A Novel Dermocosmetic Routine Containing Vitamin B3 and 2‐Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use","updated":"2025-10-06T00:09:52+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70476","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jocd.70476","url_for_landing_page":"https://doi.org/10.1111/jocd.70476"}}},"created_at":"2025-10-08T07:09:18.220Z","updated_at":"2025-10-08T07:09:18.220Z","tags":[{"paper_doi":"10.1111/jocd.70476","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"brand","value":"Liftactiv Night Cream","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"brand","value":"Liftactiv Specialist B3 Serum","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"brand","value":"Vitacid Plus Cream","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"condition","value":"Melasma","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"generic","value":"2-mercaptonicotinyl glycine","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"generic","value":"fluocinolone","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"generic","value":"hydroquinone","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"generic","value":"niacinamide","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"generic","value":"tretinoin","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"modality","value":"Topical Depigmenting Agent","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"sample_size","value":"n=91","value_numeric":91},{"paper_doi":"10.1111/jocd.70476","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"warning","value":"6‑month comparison is limited by the switch design after 3 months in the Kligman arm.","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"warning","value":"Manufacturer funding and author employment introduce potential bias.","value_numeric":null},{"paper_doi":"10.1111/jocd.70476","tag_type":"warning","value":"Single-center, women-only cohort; results may not generalize to men or Asian populations noted as absent.","value_numeric":null}],"summaries":{"what_studied":"A randomized, single-blind, 6-month trial in 91 adult women with epidermal melasma compared a dermocosmetic routine (niacinamide + 2‑mercaptonicotinyl glycine serum in the morning; night cream) used for 6 months versus Kligman triple (fluocinolone/tretinoin/hydroquinone) for 3 months then switch to the dermocosmetic. All participants used SPF 50+ twice daily; primary endpoints were MASI and mMASI at Months 3 and 6.","key_result":"At Month 3, MASI fell by 19.5% with the dermocosmetic and 30.5% with Kligman triple (both p<0.05; between-group difference not significant); at Month 6, reductions were 38.1% and 41.2%, respectively, with no between-group difference. Skin hydration improved with the dermocosmetic (+9.6% at 3 months; continued +6.3% by 6 months), did not change with Kligman triple, and increased in the switch group after Month 3 (+6.1%); tolerance favored the dermocosmetic (no local issues at 6 months: 90% vs 66%).","limitations":"Single-center, single-blind trial in women only limits generalizability. The Kligman arm switched to the dermocosmetic at 3 months, so the 6‑month comparison is not a continuous head‑to‑head; the study was industry funded and included sponsor employees among authors.","practice_takeaway":"In women with epidermal melasma, a niacinamide/2‑mercaptonicotinyl glycine dermocosmetic achieved similar 6‑month MASI reductions to Kligman triple and improved hydration with better tolerance. It is a reasonable alternative to Kligman triple or a maintenance option after a 3‑month Kligman course."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"2-mercaptonicotinyl glycine"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"2-mercaptonicotinyl glycine"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"2-mercaptonicotinyl glycine"}}}]]

Papers